Bromopride

Bromopride
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral, IM, IV
ATC code	A03FA04 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	50 to 75% (oral); 78% (intramuscular)
Protein binding	40%
Metabolism	Hepatic
Elimination half-life	4 to 5 hours
Excretion	Renal, 10 to 14% unchanged
Identifiers
	IUPAC name 4-amino-5-bromo-N-[2-(diethylamino)ethyl]-2-methoxybenzamide;
CAS Number	4093-35-0 ;
PubChem CID	2446;
DrugBank	DB09018 ;
ChemSpider	2352 ;
UNII	75473V2YZK;
KEGG	D07101 ;
ChEMBL	ChEMBL399510 ;
CompTox Dashboard (EPA)	DTXSID0045383 ;
ECHA InfoCard	100.021.675
Chemical and physical data
Formula	C14H22BrN3O2
Molar mass	344.253 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Brc1cc(c(OC)cc1N)C(=O)NCCN(CC)CC;
	InChI InChI=1S/C14H22BrN3O2/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3/h8-9H,4-7,16H2,1-3H3,(H,17,19) ; Key:GIYAQDDTCWHPPL-UHFFFAOYSA-N ;
	(what is this?) (verify)

Bromopride (INN) is a dopamine antagonist with prokinetic properties widely used as an antiemetic, closely related to metoclopramide. It is not available in the United States.

Bromopride appears to be safe and effective for use in pregnancy.^[1]

Indications

Bromopride is indicated in the treatment of nausea and vomiting, including postoperative nausea and vomiting (PONV); gastroesophageal reflux disease (GERD/GORD); and as preparation for endoscopy and radiographic studies of the gastrointestinal tract. The manufacturer also claims it is valuable in, among other indications, hiccups and gastrointestinal adverse effects of radiation therapy.

Adverse effects

Bromopride is generally well tolerated; the most common adverse effects of its use are somnolence and fatigue. Bromopride may rarely cause extrapyramidal symptoms and, as with metoclopramide, may increase prolactin levels.^[2]

Chemistry

Bromopride is a substituted benzamide, closely related to metoclopramide.^[3] It is identical to metoclopramide except for the presence of a bromine atom where metoclopramide has a chlorine substituent.

Availability

Bromopride is not available in the United States or the United Kingdom. It is marketed in Brazil by Sanofi-Synthélabo under the trade name Digesan, by LIBBS under the name Plamet, and as a generic drug.

References

^ Araújo JR (1981). "Evaluation of bromopride in nausea and vomiting of pregnancy". J Bras Ginecol (in Portuguese). 91 (4): 283–5.
^ "Bula do Profissional de Saúde: Bromoprida". Bulário Eletrônico da Anvisa (in Portuguese). Brazilian National Health Surveillance Agency. April 11, 2006. Archived from the original on September 28, 2007. Retrieved 2007-07-23.
^ Brodie RR, Chasseaud LF, Darragh A, Lambe RF, Rooney L, Taylor T (1986). "Pharmacokinetics and bioavailability of the anti-emetic agent bromopride". Biopharm Drug Dispos. 7 (3): 215–22. doi:10.1002/bdd.2510070302. PMID 3730521.

[1] Araújo JR (1981). "Evaluation of bromopride in nausea and vomiting of pregnancy". J Bras Ginecol (in Portuguese). 91 (4): 283–5.

[2] "Bula do Profissional de Saúde: Bromoprida". Bulário Eletrônico da Anvisa (in Portuguese). Brazilian National Health Surveillance Agency. April 11, 2006. Archived from the original on September 28, 2007. Retrieved 2007-07-23.

[3] Brodie RR, Chasseaud LF, Darragh A, Lambe RF, Rooney L, Taylor T (1986). "Pharmacokinetics and bioavailability of the anti-emetic agent bromopride". Biopharm Drug Dispos. 7 (3): 215–22. doi:10.1002/bdd.2510070302. PMID 3730521.

[1]

[2]

[3]